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Abstract
Background: Shortened treatment regimens for tuberculosis are under development to improve treatment
outcomes and reduce costs. We estimated potential savings from a societal perspective in Brazil following the
introduction of a hypothetical four-month regimen for tuberculosis treatment.
Methods: Data were gathered in ten randomly selected health facilities in Rio de Janeiro. Health service costs were
estimated using an ingredient approach. Patient costs were estimated from a questionnaire administered to 126
patients. Costs per visits and per case treated were analysed according to the type of therapy: self-administered
treatment (SAT), community- and facility-directly observed treatment (community-DOT, facility-DOT).
Results: During the last 2 months of treatment, the largest savings could be expected for community-DOT; on
average USD 17,351-18,203 and USD 43,660-45,856 (bottom-up and top-down estimates) per clinic. Savings to
patients could also be expected as the median (interquartile range) patient-related costs during the two last
months were USD 108 (13–291), USD 93 (36–239) and USD 11 (7–126), respectively for SAT, facility-DOT and
community-DOT.
Conclusion: Introducing a four-month regimen may result in significant cost savings for both the health service
and patients, especially the poorest. In particular, a community-DOT strategy, including treatment at home, could
maximise health services savings while limiting patient costs. Our cost estimates are likely to be conservative because a
4-month regimen could hypothetically increase the proportion of patients cured by reducing the number of
patients defaulting and we did not include the possible cost benefits from the subsequent prevention of costs
due to downstream transmission averted and rapid clinical improvement with less side effects in the last two
months.
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Background
Globally, in 2013, there were nine million new cases and
1.5 million deaths from tuberculosis (TB), with 95 % of
the deaths occurring in low- and middle-income countries
[1]. Major advances in diagnostic technologies [2–6] and
an increase in treatment coverage [1] have largely contrib-
uted to improvements in TB control worldwide. However,
the length of the current first-line standard regimen (total
of six months, including a 2-month intensive phase with
four drugs and a 4-month continuation phase with two
drugs), as well as the side effects of this treatment, con-
tinue to hamper treatment adherence and acceptability. In
addition, treatment costs represent a substantial expend-
iture for National TB Programmes (NTP) [1, 7], while the
costs borne by patients can be disproportionally high con-
sidering the poorest subgroups of the population affected
by the disease [8, 9]. Thus, substantial investments and
international efforts are being put into the development of
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shortened new regimens, mainly aiming to reduce the
length of the continuation phase [10–13].
Brazil has been an early adopter of new technologies in
general and of new TB technologies in particular [14, 15].
Accurate information on costs is an important input for
planning and budgeting by the Brazilian NTP when con-
sidering funding the introduction of new technologies.
Introducing a 4-month regimen for TB in a high service
cost scenario, such as Brazil, may lead to overall savings
from the health service perceptive [16]. However, initial
published estimates have been based on global estimates of
treatment costs from the World Health Organisation
(WHO), rather than locally-collected data and have ex-
cluded costs from a patient perspective [16]. Yet, the im-
portance of including patient cost into policy decisions is
reflected in and will help track progress of WHO’s post-
2035 targets, which include a statement that no household
should suffer from catastrophic expenditures related to TB
[17]. Previous studies suggest that cost savings from the
patient side may be an important advantage of shortened
TB regimens. Patient costs during the last two months of
first-line treatment were recently shown to correspond to
89 and 77 % of the 2-month average national incomes in
Tanzania and Bangladesh [18]. However, to date, there is
scarce information about actual resource utilisation, treat-
ment models in place, and how costs related to TB treat-
ment (for patients or the health service) vary depending on
the treatment model used. Thus, the purpose of this study
is to assess health service and patient costs during the last
two months of the current first-line regimen and to explore
potential savings following the introduction of a 4-month
regimen in Rio de Janeiro, Brazil.
Methods
Study setting
The city of Rio de Janeiro has one of the highest TB in-
cidence rates in Brazil [19], with 90 new cases per
100,000 population reported yearly [19]. This high inci-
dence has been linked to structural determinants such
as urban violence, poverty, social inequity, and a com-
plex healthcare system [20]. Although, nationally, all TB
treatment is available through public facilities free-of-
charge and supervised treatment is mandatory, there is
important variation among clinics of the treatment
models offered. Currently, there are three types of pri-
mary care facilities in Rio [21]: (i) family health clinics,
where family health teams composed of one physician,
one nurse, one aid nurse, and six community healthcare
workers provide home visits and clinic-based consulta-
tions. Each team is responsible for 1,000 to 1,500 fam-
ilies living in their catchment area; (ii) classic health
facilities, where only scheduled appointments with gen-
eral physicians, specialists, and nurses are available; and
(iii) mixed clinics providing both types of services. All
facilities provide self-administered therapy (SAT) for TB
treatment. However, not all clinics have implemented
directly observed therapy (DOT); in those where it has
been implemented, two treatment models are available:
facility-based and community-based DOT (facility-DOT
and community-DOT). Facility-DOT patients have to
present to the clinics for pill collection and intake; while
community-DOT patients receive daily visits from
health care agents distributing pills and supervising in-
take on working days. The frequency of supervision may
also vary across facilities - at least three times weekly,
ideally five times, during the first 2 months; twice
weekly, ideally five times, for the remaining 4 months of
treatment [22] All patients have monthly visits with a
physician for clinical, bacteriological and (eventually) radio-
logical evaluation, regardless of the treatment model.
Data collection and analysis
To ensure a representative range of costs estimates from
different settings, we purposively selected four geograph-
ical areas to obtain a balance between the municipality
of Rio and peri-urban areas. We then randomly sampled
12 facilities from a census of all eligible facilities cur-
rently treating at least 50 TB patients (excluding hospi-
tals), stratified by workload (ratio of TB patients per
healthcare workers) and type of clinic (family health
clinics, classic health facilities, and mixed clinics).
Health service costs
Costs from a healthcare provider’s perspective were esti-
mated using an ingredient approach [23–25] for each
participating facility. We included capital costs (building,
equipment, furniture) and recurrent costs (labour, sup-
plies, utilities, drugs, and monitoring and evaluation).
We interviewed personnel, observed consultations and
reviewed financial and activity reports to estimate the re-
source use for each input. In cases where resources were
shared between TB and other services, we used the fol-
lowing allocation methods: costs for building space were
estimated by multiplying the total building space by the
average rental price per square meter, sourced from local
rental offices. Building space was then allocated accord-
ing to service distribution within the clinic’s rooms and
time used (from staff interviews and observations). For
equipment and furniture, we sourced local market prices
for all items and allocated to TB proportionally to the
time used and number of patients (from staff interviews
and clinic records); staff time dedicated to TB was allo-
cated following observations of practices and staff
interviews.
We used a combination of bottom-up and top-down
approaches to calculate unit costs. In a bottom-up ap-
proach, we identified the resources used within a certain
input type and after allocating a value to them, we added
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them to calculate unit costs; for the top-down approach,
we divided the total expenditure for a given input type
by the units of activity. We adopted a micro-costing ap-
proach that mixed both methods. Drug costs are only re-
ported as bottom-up estimates because records for drug
expenditures were not reliable at facility-level. In Brazil,
drug expenditure is centralized; and therefore not ac-
cessible at the facility level. We verified the prices of
drugs and consumables sourced from suppliers with
international databases [26]. Capital costs were annual-
ized and discounted at 3 % per year. All prices were col-
lected in local currency.
We calculated cost per visit and episode costs (cost
per person treated) by treatment modality and site. We
extracted information on the total number of non-
multidrug resistant TB patients being treated for each
treatment modality (SAT, facility- and community-DOT)
from service statistics for the period covered. We esti-
mated the episode costs by month by multiplying the
number of visits in this period by the unit costs. To allo-
cate costs to the last two months of treatment, we first
estimated the number of visits using two methods: (i) as-
suming a 10 % default rate after the 4th month, we esti-
mated that the number of monthly visits would be 45 %
of the number of visits if guidelines were fully adhered
to; (ii) we estimated the number of visits during the last
two months as reported by patients in the question-
naires. We did not include programme costs, defined as
the costs associated with general support to service de-
livery (i.e., not directly linked to individual patients; for
example administration, management, and supervision
activities).
Finally, we estimated the total potential annual savings
due to the introduction of a shortened first-line TB regi-
men considering that 76,020 persons were treated with
TB in 2013 [1] and assuming a distribution of treatment
models as seen in our participating clinics.
Patient costs
All TB patients attending (or having home visits by a
community health worker) at a participating clinic on
their 5th or 6th month of treatment were invited to par-
ticipate. After obtaining informed consent, data on
demographics, assets, type of TB treatment and both
direct and indirect costs were gathered. The question-
naire used to collect patient-related costs was based on a
validated tool for patient costs developed by USAID and
available online [27]. Direct costs included all out-of-
pocket expenditure, while indirect costs included prod-
uctivity loss/opportunity cost to the household, coping
costs (selling of assets and borrowed money) and carer’s
costs. With regards to productivity loss/opportunity
costs to the household, we considered both transport
time seeking care and additional days off-work due to
the disease. The value of an hour was estimated using
four different methods: (i) 2013 minimum wage; (ii)
midpoint of the estimated family monthly income using
Critério Brasil [28] divided by the number of persons liv-
ing in the house; (iii) the shadow salary [29], estimated
using the union’s hourly salary, according to the profes-
sion declared (for those without employment, we valued
their hourly cost based on the minimal wage); and (iv)
the declared income. We assumed a 44-hour weekly
contract for participants employed [30].
Costs per visit were multiplied by the number of visits
in the last 2 months to arrive at total costs. We calcu-
lated the ratio of total costs during the last 2 months of
treatment to the estimated monthly income by estima-
tion method. We considered total costs during the last
2 months to be catastrophic when they represented over
40 % of the monthly income [31].
Data collection took place from June 2013 to May
2014. The average exchange rate used was USD 1 = BRL
2.16. All health service cost analyses were performed
using EXCEL 2013 (Microsoft, USA). Statistics analyses
were performed in SPSS 21 (IBM, USA). Mean costs and
standard deviations (SD) were compared using inde-
pendent t-test.
Ethical approval
The study was approved by the Institutional Review
Board at the Universidade Gama Filho (268.778) in Rio
de Janeiro; the Comitê de Ética em Pesquisa, Prefeitura
do Rio de Janeiro (164A/2013); and the Observational
and Interventions Research Ethics Committee of the
London School of Hygiene and Tropical Medicine, UK
(6322).
Results
The 12 randomly selected clinics provided services to
neighbourhoods with a wide range of income (average
monthly income USD 209-USD 2,538) and TB burden
(incidence rate 51.2–382.4 new TB cases per 100,000
population per year). All facilities offered SAT and at
least one type of DOT (9 offered facility- DOT while the
other three offered community-DOT). The facilities pre-
sented a wide workload range (50–383 staff registered;
66–332 patients per year). Of 12 clinics approached, ten
(83.3 %) agreed to participate (Table 1).
Health service costs
Service utilisation for TB is presented by facility in
Additional file 1: Table S1 in the supplementary
material. A total of 1,140 TB patients were treated
during 2013. Of these, seven were multidrug-resistant
TB patients (0.6 %) treated in one facility only. These
patients were not included in the analysis. Of the
1,133 new or previously treated TB patients, 739
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(65 %) were DOT patients (530, 47 % in facility-DOT
and 209, 18 % in community-DOT). The total num-
ber of visits was estimated to be 55,876, of which
37 % (n = 20,691) were community visits. Only 4 % of
all visits (n = 2,325) were SAT visits.
The unit and total costs by treatment type as well as
drug and episode costs by treatment phase and type are
presented in Additional file 1: Table S2 in supplementary
material. Detailed unit costs by cost input are displayed
in Additional file 1: Table S3, also in supplementary ma-
terial. Briefly, the highest mean unit cost excluding drugs
was estimated for SAT at USD 31.1 (range 8.0–93.1) and
USD 61.1 (range 18.3–264.4); the estimates for facility-
DOT were USD 8.2 (range 3.9–19.7) and USD 14.8
(range 5.3–21.7); while for community-DOT, these were
USD 5.4 (range 5.2–5.7) and USD 14.5 (range 13.0–16.0),
bottom-up and top-down respectively. The highest mean
cost per patient completing treatment was observed for
community-DOT (USD 571.1 and USD 1,477, bottom-up
and top-down respectively) but varied greatly among sites
(ranges 549.2–594.1 and 1,331–1,623). Mean total annual
costs per facility were estimated at USD 43,439 and
81,465, bottom-up and top-down respectively. Staff and
building costs represented the main type of costs in both
SAT and facility- DOT, whereas for community- DOT, the
main driver of costs was staff and overhead costs
(Additional file 1: Table S3).
Table 2 presents the mean potential cost savings in the
last two months of treatment by utilisation assumption
(see Additional file 1: Table S4 for top-down estimates
and Additional file 1: Table S5 for bottom-up estimates
by site). Our estimated savings varied by clinic and type
of treatment. The largest savings could be expected for
community-DOT, reaching for example, up to USD
67,226 (Additional file 1: Table S4) at a single clinic. We
estimated that the national introduction of a shortened
regimen could potentially save up to USD 8,345,775 and
16,166,046 (top-down and bottom-up estimates) savings
in treatment costs related to the two last months of
treatment.
Patient costs
We interviewed a total of 126 patients in the ten partici-
pating clinics. The median age among our sample was
43.0 (interquartile range 27.8–55.4) years, 61 % (n = 77)
were male, 78 % (n = 93) belonged to the three lowest
socioeconomic classes. Participants’ characteristics are
detailed in Additional file 1: Table S6 in supplementary
material.
The estimated value of a productive hour using the
different methods was: (i) minimum wage, USD 1.4/h;
(ii) family monthly income per capita, USD 1.0 (IQR
0.7–1.8)/h; (iii) shadow price, USD 2.1 (IQR 2.0–2.2)/h;
and (iv) declared income, USD 1.9 (IQR 1.5–3.2)/h.
Among patients declaring their income (n = 49), the
median declared monthly income was USD 370 (IQR
298–625). Using the shadow salary method, the median
monthly income was USD 420 (IQR 405–435); while
using the family income per capita, the median monthly
income was estimated at USD 195 (IQR 133–359).
Table 3 shows direct costs as well as indirect by
method to value a productive hour. Mean direct costs
during the last 2 months were USD 96 for the whole
sample. The mean total indirect costs varied depending
Table 1 Characteristics of all randomly selected clinics
Study
Information
Clinic information Neighbourhood information
Clinic Included n FTE
staff
n TB
patients/
year
Type [43] TB treatment model Population
(2010) [44]
TB incidence
ratea [45]
Average monthly income
(2013USD) [44]
1 No 137 [43] 76 [43] Family health clinic SAT and community-DOT 10,086 152.2 2,538.1
2 Yes 56 51 Family health clinic SAT and community-DOT 7,390 51.2 610.3
3 Yes 147 163 Family health clinic SAT and community-DOT 58,007 382.4 208.8
4 Yes 89 117 Mixed clinic SAT and facility-DOT 23,861 220.0 401.5
5 Yes 138.5 66 Mixed clinic SAT and facility-DOT 133,315 108.1 356.0
6 Yes 173.5 98 Classic health facility SAT and facility-DOT 286,527 79.7 387.8
7 Yes 268 26 Classic health facility SAT and facility-DOT 182,722 109.4 249.2
8 Yes 111 132 Mixed clinic SAT and facility-DOT 137,710 103.0 1,253.6
9 Yes 188 195 Mixed clinic SAT and facility-DOT 41,524 112.8 357.5
10 Yes 76.5 107 Mixed clinic SAT and facility-DOT 14,794 95.6 1,835.7
11 Yes 256 178 Classic health facility SAT and facility-DOT 211,068 167.2 315.6
12 No 201 [43] 254 [43] Mixed clinic SAT and facility-DOT 33,180 56.8 480.8
aper 100,000 inhabitants, in 2009; n number; FTE full-time equivalent; SAT self-administered therapy; DOT directly observed therapy
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on the method used to value a productive hour: using
the minimum wage and the SES income per capita, the
mean total indirect costs was USD 316; using the
income per activity, this was USD 332 for the whole
sample. If we restrict the sample to those reporting an
income, then the mean total indirect costs is estimated
at USD 357.
When comparing the mean total costs by participant’s
characteristics, these were higher for patients belonging
to lower socioeconomic classes (mainly due to higher in-
direct costs), and patients under SAT and facility-DOT
regimens (Table 4). However, while the difference was
statistically significant when comparing socioeconomic
classes, it was not statistically significant when compar-
ing type of treatment. Total costs during the last two
months of treatment corresponded to a maximum of
26.3 % (1.6–41.8 %) if minimum wage method was con-
sidered and a minimum of 10.4 % (1.4–41.8 %) when in-
come per capita for the socio-economic class was
considered. These proportions of the income attaining
over 40 % for 56 (44 %) patients and 34 (27 %)
respectively (Additional file 1: Table S7 in supplementary
material).
Discussion
We present a comprehensive cost study describing de-
tailed information on first-line regimen costs that can
serve as an input for decision-making and budget prep-
aration for NTPs when considering the introduction of
new shortened regimens. We estimated the methods of
delivery to be the main driver of overall costs. From a
health service perspective, community-DOT was the
main contributor to total costs for first-line TB treat-
ment in these primary care facilities, mainly due to high
service utilisation (domiciliary visits by community
health care agents). SAT was estimated to be the treat-
ment modality with the highest unit cost, even though it
was the treatment model contributing the least to total
costs, due to the least number of visits. From a patient
perspective, facility-based services (both SAT and
facility-DOT) were modalities representing the highest
costs for the patients, mainly associated to transport and
Table 2 Potential savings: episode and total costs by type of treatment in the last two months for different utilisation assumptions,
USD 2013
Top-down; mean (range) Bottom-up; mean (range)
EPISODE COSTS
Facility-DOT
45 % continuation phase 283.7 (108.5–410.5) 160.6 (82.7–373.3)
Patient utilisation 286.9 (109.6–415.2) 162.3 (83.5–377.6)
SAT
45 % continuation phase 115.1 (38.9–470.8) 61.6 (20.8–168.5)
Patient utilisation 127.7 (42.6–525.0) 68.0 (22.4–187.6)
Community-DOT
45 % continuation phase 441.5 (397.6–485.6) 169.8 (162.8–176.8)
Patient utilisation 463.8 (417.6–510.1) 178.1 (170.8–185.6)
Average total costs by treatment type
Facility-DOT
45 % continuation phase 16,834 (2,824–24,631) 10,083 (848–18,260)
Patient utilisation 17,024 (2,855–24,911) 10,194 (857–18,467)
SAT
45 % continuation phase 2,021 (65.6–4,701) 1,287 (55.4–3,562)
Patient utilisation 2,227 (72.5–5,157) 1,407 (61.1–3,884)
Community-DOT
45 % continuation phase 43,660 (23,308–64,012) 17,351 (8,486–26,216)
Patient utilisation 45,856 (24,486–67,226) 18,203 (8,907–27,500)
Average total costs per facility
45 % continuation phase 24,221 (4,010–64,954) 12,824 (1,316–26,551)
Patient utilisation 25,018 (4,159–68,276) 13,204 (1358–27873)
DOT directly observed therapy; SAT self-administered therapy
Utilisation assumptions: 1) 45 % continuation phase. In this scenario we calculated the costs in the last two months of treatment as a proportion of the continuation phase
costs; 2) Patient utilisation. In this alternative scenario, costs in the last two months of treatment are calculated using the reported number of visits by patients interviewed
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productivity loss costs. Therefore, while bringing ser-
vices to the community might seem more costly from a
health service perspective, it can lead to substantial sav-
ings from a societal perspective. Besides costs, decision-
makers should take into account the potential improve-
ment brought by community-based treatment regarding
treatment outcomes and equity in the access to care for
an already vulnerable population. While the patient-level
benefits of community-DOT compared to facility-DOT
have been suggested in three clinical trials, the benefits
of DOT over SAT are still controversial [32, 33]. Add-
itionally, although general access to care and healthcare
utilization has improved with the Family Health Pro-
gram expansion in Brazil [34], TB treatment outcomes
have not [35].
In terms of cost differences among models of service de-
livery, our results are consistent with two previous studies
in the country [7, 36]. However, Steffen et al. estimates were
based on staff costs exclusively and the authors assumed
that service utilisation at the facility-level was the same for
SAT or DOT, but much lower for pill collection visits,
explaining the lower cost estimates for the pill collecting
visits at USD 7.5 (USD 9.4 in 2012) [7]. In addition, at the
time of study (2008), community-DOT was the exception
in Rio de Janeiro. Although they found SAT to be more
cost-effective than DOT, community-DOT was not evalu-
ated. In our study, community-DOT was the strategy with
the lowest unit costs, both from the health service and
patient perspectives.
We found a large variation both across clinics and be-
tween the top-down and bottom-up approaches, mainly
due to estimations of staff time. While a top-down
method might be less precise when disaggregating costs
per activity, especially for staff costs allocation, it might
be a more accurate representation of total costs, includ-
ing inefficiencies in service delivery. Compared to the
USD 88,000,000 national budget for TB control, the po-
tential estimated savings should a four-month regimen
be introduced nationally could represent up to 9–18 %
of the NTP budget. These savings could be realised in
their totality if, for example, staff would be relocated to
other programmes. As this might not be the case, we are
offering a top end estimate of potential savings. On the
other hand, our estimates of potential cost benefits are
likely to be conservative because potential savings due to
a possible reduction in transmission and the possible dif-
ferential in health improvements, with less side effects
and therefore service utilisation during the last months
of treatment, were not considered.
Costs of treatment for patients can be a significant barrier
to access and utilisation of healthcare [18, 37–39], even in
health systems where drugs and services are free-of-charge,
as is the case in Brazil. In the present study, during the two
last months of treatment, when patients have usually recov-
ered from symptoms present at diagnosis and are often fit
to work, the costs incurred by patients still represent a
substantial proportion of their income. We estimated that
the introduction of shortened regimens may prevent
Table 3 Total, direct and indirect costs incurred by patients during the last two months of treatment in Rio de Janeiro, Brazil (using
four methods for productivity loss valuationa), USD 2013
Costs Minimum wage,
mean (SD) N = 126
SES income per capita,
mean (SD) N = 126
Income per activity,
mean (SD) N = 126
Reported income,
mean (SD) N = 49
Total direct costs (all)b 96 (148) 114 (162)
Transport 8 (19) 5 (11)
Food 2 (5) 2 (5)
Other non-transport/food 3 (21) 0.5 (3)
Nutritional supplements 82 (143) 105 (158)
Total indirect costs (all)b 316 (1,466) 316 (1,469) 332 (1,472) 357 (1,985)
Coping costsd 275 (1,458) 327 (1,982)
Productivity loss 21 (24) 18 (26) 30 (32) 25 (39)
Caregiver/guardian costs 20 (67) 22 (78) 27 (94) 5 (23)
Total costs (all)b 413 (1,503) 413 (1,507) 153 (206) 144 (163)
Total costs (patients only)c 361 (1,481) 364 (1,484) 374 (1,486) 411 (1,991)
Total direct costs 51 (74) 57 (77)
Total indirect costs 310 (1,466) 313 (1,469) 323 (1,471) 354 (1,981)
aMinimum wage refers to the valuation of an productive hour lost based on the minimum wage in Brazil and a 44 weekly hour contract; SES income per capita refers to the
valuation of a productive hour based on the average income for a reported socio-economic status; Income activity refers to the valuation of a productive hour based on the
average income for the patient’s profession, based on union’s information; Reported income refers to the valuation of a productive hour based on the income reported by
the participant. bThese costs are presented for both patients and any person accompanying the patient during their visits. cThese costs refer to costs incurred by patients
only, not including costs incurred by any accompanying person. dCoping costs include borrowed money and selling of assets
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catastrophic expenditure for 27 to 44 % of individuals in
our sample, depending on the method used to estimate the
value of a productive hour. This result is comparable to
previous results in Tanzania and Bangladesh, where the
total patients costs of six months of treatment represented
103 and 117 % of the per capita income, respectively [18].
In our study, costs for patients were significantly
higher for those in the lower socioeconomic classes. Be-
cause their productive hour is less valued, we would ex-
pect lower indirect costs. Our finding (higher indirect
costs) suggests that, no matter which method is used to
estimate them, more hours are spent in or traveling to
the facilities and raises more concern about the added
vulnerability to an already disadvantaged population.
The introduction of a shortened regimen would then
benefit lower socio-economic class patients the most.
Our study presents several limitations. We collected
data in one only city, including both urban and peri-
urban but excluding rural settings. Therefore, the find-
ings can only be generalised to similar settings within
Brazil. Additionally, we present potential cost savings
during the last 2 months of treatment only and patients
incur substantial costs during the pre-diagnosis period
[40–42]. In our analysis, we assumed that these costs
(pre-diagnosis) would not change, should a shortened
regimen be introduced. Additionally, while we aimed
to report income loss, this measure might not repre-
sent societal productivity loss (due to replacement).
An additional limitation is the use of routine data to
measure service utilisation. Program indicators re-
ported patients by treatment delivery model but not
by treatment phase. The assumptions made about the
distribution between patients in the intensive as
opposed to continuation phase may have led to an
over-estimation of unit costs. Conversely, the study
presents significant strengths. Detailed cost data were
collected from a societal perspective, from patients
and clinics in diverse neighbourhoods adopting differ-
ent models of treatment. Finally, when faced with un-
certainty in assumptions such as the value of a
productive hour and the distribution of patients
between intensive and continuation phase, we present
several estimation methods to test the robustness of
our conclusions to these assumptions.
Table 4 Factors associated with costs incurred by patients during the last two months of treatment in Rio de Janeiro, using income
per activity reported by participant to value a productive hour (USD 2013)
Variables Number in each category
with direct costs
Direct costs, mean
(SD) N = 85b
P
valuea
Indirect costs, mean
(SD) N = 126
P
valuea
Total costs, mean
(SD) N = 126
P-
valuea
Sexb
Female 32 79 (126) 0.313 355 (1,981) 0.892 127 (145) 0.263
Male 53 107 (161) 318 (1,040) 169 (236)
Age
< 43 years 41 105 (165) 0.527 289 (998) 0.743 167 (251) 0.451
> = 43 years 44 88 (131) 375 (1834) 139 (139)
Treatment history
New case 71 101 (155) 0.544 373 (1,628) 0.524 153 (217) 0.952
Retreatment 14 80 (116) 159 (299) 150 (157)
Residence
Urban 56 88 (152) 0.351 258 (978) 0.386 135 (213) 0.166
Peri-urban 29 114 (140) 500 (2,193) 190 (187)
Treatment type
SAT 52 110 (165) 0.379 560 (49) 0.216 170 (256) 0.333
Facility-DOT 29 93 (137) 126 (185) 154 (142)
Community-DOT 4 52 (104) 39 (49) 81 (122)
Socioeconomic statusc
A/B (median family income
USD 4288.4-USD 1228.7)
18 60 (108) 0.128 68 (137) 0.042 98 (121) 0.099
C/D/E (median family income
USD 780.1-USD 359.2)
64 111 (160) 428 (1,703) 175 (227)
Abbreviations: SAT self-administered therapy; DOT directly observed therapy; SD standard deviation
*from independent t-test
bAmong 126 patients, 85 patients or accompanying persons declared direct costs
cmissing information for 3 participants
Bold numbers highlight significant p-values.
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Conclusion
Altogether, our findings show that significant savings can
be achieved for patients and the health system with the
introduction of shortened regimens. This is an important
finding that sustains the rationale for shorter regimens
even with equivalent effectiveness to the currently recom-
mended 6-month regimen. We also highlighted the im-
portance of considering the variation among models of
delivery when undertaking cost-effectiveness analyses of
future drugs. As the numbers of confirmed TB patients
may increase with the introduction of new diagnostics
[14], potentially reducing the number of patients empiric-
ally treated, it will be important to continue investing on
TB programs, not only due to the potential health impact
on patients outcomes but also to achieve potential cost
gains, helping to avoid catastrophic costs for patients and
to attain the post-2015 targets.
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